BOLT vs C · rev $7.7M vs P/E 16, rev $85.22B
Bolt Biotherapeutics (BOLT) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
BOLT currently screens at market cap $11.3M. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the BOLT and C stock pages for the full models.
Not investment advice.